Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Acute 12Myelodysplastic Syndromes 11Hodgkin Disease 8Lymphoma, Non-Hodgkin 7Multiple Myeloma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Myelomonocytic, Chronic 5Myeloproliferative Disorders 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Burkitt Lymphoma 4Anemia, Refractory, with Excess of Blasts 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Colorectal Neoplasms 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Stomach Neoplasms 2Sarcoma 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroblastoma 2Neoplasms, Plasma Cell 2

Interventions

Carboplatin 3fludarabine 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Cyclophosphamide 2Cisplatin 2Cerebral Decortication 2pembrolizumab 1fludarabine phosphate 1Platinum 1Fluorodeoxyglucose F18 1Blood Component Removal 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × fludarabine phosphate × 30 days × Clear all
NCT03935893 2026-06-01

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

University of Pittsburgh

Phase 2 Active not recruiting
20 enrolled
DermatologicEndocrineGastrointestinalNETOther solid neoplasmSarcomaThoracic

Turcot syndrome, Mesothelioma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Neuroendocrine Tumors, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡